Alzheimer's disease
Conditions
Interventions
971Group:Take 971 Targeting Aß Manno-oligosaccharide Diacid Capsules orally
Rivastigmine group:Take rivastigmine orally
Placebo group:Take placebo group orally
Sponsors
Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Outpatients or inpatients aged 50-80 years and elderly residents of the community, regardless of gender, education level >= 6 years; 2. According to the neuropsychological scale and clinical symptoms, it is determined that there is cognitive impairment; 3. The subjects have not used other drugs that improve cognitive impairment before the test; 4. Diagnostic criteria: MCI (CDR=0.5) or mild Alzheimer's disease (CDR=1 point).
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, liver, and renal insufficiency (Note: severe liver insufficiency refers to ALT value > 2 times the upper limit of normal or AST value > 2 times the upper limit of normal; severe renal insufficiency refers to creatinine value > 1.5 times the upper limit of normal); 2. Participants with other mental and nervous system diseases and malignant tumors; 3. Geriatric Depression Scale (GDS) score < 10 points, excluding cognitive impairment caused by depression; 4. Those who have poor compliance or are dying of life and cannot complete the course of treatment; 5. Use other cognitive improvement drugs such as ChEIs or other psychotropic drugs within the past three months; 6. Those who are participating in other clinical drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AVLT score; | — |
Secondary
| Measure | Time frame |
|---|---|
| ADAS-cog/MMSE score; | — |
Countries
China
Contacts
Public ContactSun Wei
Xuanwu Hospital, Capital Medical University
Outcome results
None listed